Envista’s (NVST) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Envista (NYSE:NVST) in a research report report published on Tuesday morning, Benzinga reports.

Several other research firms have also recently issued reports on NVST. The Goldman Sachs Group lowered their price objective on shares of Envista from $20.00 to $17.50 and set a sell rating for the company in a research report on Friday, May 3rd. Robert W. Baird lowered their price objective on shares of Envista from $22.00 to $19.00 and set a neutral rating for the company in a research report on Thursday, May 2nd. Evercore ISI lowered their price objective on shares of Envista from $24.00 to $19.00 and set an outperform rating for the company in a research report on Tuesday, June 25th. JPMorgan Chase & Co. lowered their price objective on shares of Envista from $29.00 to $23.00 and set an overweight rating for the company in a research report on Thursday, May 2nd. Finally, Morgan Stanley cut shares of Envista from an overweight rating to an equal weight rating and lowered their price objective for the company from $33.00 to $21.00 in a research report on Friday, April 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of Hold and an average target price of $22.85.

Envista Price Performance

Envista stock opened at $16.50 on Tuesday. The company’s 50-day moving average price is $17.54 and its 200-day moving average price is $20.34. Envista has a twelve month low of $15.69 and a twelve month high of $36.14. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.93 and a current ratio of 2.27.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.05). The firm had revenue of $623.60 million for the quarter, compared to the consensus estimate of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.38 earnings per share. Analysts predict that Envista will post 1.19 earnings per share for the current year.

Institutional Investors Weigh In On Envista

Several institutional investors have recently bought and sold shares of NVST. Fifth Third Bancorp raised its holdings in shares of Envista by 98.1% in the fourth quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after buying an additional 621 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after buying an additional 2,940 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Envista by 1,297.9% in the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after buying an additional 2,427 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Envista by 538.0% in the fourth quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock worth $77,000 after buying an additional 2,706 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Envista by 15.4% in the fourth quarter. Van ECK Associates Corp now owns 5,646 shares of the company’s stock worth $136,000 after buying an additional 755 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.